Marta B. Afonso

PhD (2017) in Pharmacy (Cellular and Molecular Biology), Faculdade de Farmácia, Universidade de Lisboa

Post-Doctoral Fellow, iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa

 

Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

T (+351) 217 946 496
F (+351) 217 946 491
Researcher ID N-5202-2017
Group Researcher ID A-4244-2014
Scopus Author ID 55428400900

Research Interests

Afonso’s work is focused on a better understanding of the role of necroptosis and miRNAs in the pathogenesis of several liver diseases, namely non-alcoholic fatty liver disease (NAFLD), cholestasis and hepatocellular carcinoma, while critically evaluating the therapeutic potential and eventual adverse events resulting from pathway inhibition. She also aims to build a platform for discovery and early development of innovative therapeutic approaches for cancer prevention and treatment.

 

Selected Publications

Afonso MB, Rodrigues CMP. microRevolution in understanding primary biliary cholangitis pathophysiology. Hepatology 2018; 67: 1213-15.

Afonso MB, Rodrigues PM, Simão AL, Gaspar MM, Carvalho T, Borralho P, Banales JM, Castro RE, Rodrigues CMP. miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. Cell Death Differ 2017; doi: 10.1038/s41418-017-0019-x. [Epub ahead of print]

Afonso MB, Rodrigues PM, Simão AL, Ofengeim D, Carvalho T, Amaral JD, Gaspar MM, Cortez-Pinto H, Castro RE, Yuan J, Rodrigues CMP. Activation of necroptosis in human and experimental cholestasis. Cell Death Dis 2016; 7(9): e2390.

Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, Castro RE, Rodrigues CMP.  Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond) 2015; 129: 721-39.

Castro RE, Ferreira DMS, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CMP. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in rat liver and activated by disease severity in human non-alcoholic fatty liver disease.  J Hepatol 2013; 58: 119-25.